The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
The healthcare provider organizations are tasked with managing patient enrollment in the Precision Medicine Initiative.
The Pharmacogenomics Clinical Annotation Tool interprets variants from sequencing or genotyping tests and generates a report to inform prescribing decisions.
Geisinger Health System's MyCode Community Health Initiative has signed up more than 100,000 participants and has returned results to about 100 patients.
The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
Geisinger will use the funding to trial its GenomeFIRST Medicine program, which aims to integrate genetic results into standard patient care.
The Geisinger Health System team found 241 genes, including 17 new ones, which could be related to autism, schizophrenia, and other disorders.
Geisinger is returning actionable results from 76 genes in order to study how genomics can be integrated into a healthcare setting to guide patient management.
The research will focus on the genetic factors behind the variable phenotypes observed in patients with developmental brain disorders such as schizophrenia and autism.
Drug companies are rushing toward genomic databases to inform their searches for new drugs, Reuters reports.
A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.
Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.
In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.
A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.